A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Trial Profile

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms STRENGTH
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Mar 2018 According to an Acasti Pharma media release, the company believes that the ongoing outcome studies (REDUCE-IT and STRENGTH) if positive, may greatly expand the omega-3 drug market in the U.S. to include a broader range of patients with high HTG (200 mg/dL - 499 mg/dL) and these outcome trials are expected to report by the end of the third quarter of 2018 (REDUCE-IT) and in 2019 (STRENGTH).
    • 03 Nov 2017 Planned End Date changed from 29 Nov 2019 to 31 Oct 2019.
    • 03 Nov 2017 Planned primary completion date changed from 29 Nov 2019 to 31 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top